News
The symptoms can include nerve pain, emotional numbness and sexual dysfunction and can last for years after stopping the ...
A GLP-1/glucagon dual agonist conferred weight loss of up to 12.55% at 32 weeks for adults with overweight or obesity, ...
The newly recommended dosing schedule significantly lowered ARIA-E rates compared to the original dosing schedule, adding to the established safety profile of the treatment INDIANAPOLIS, ...
President Trump has threatened to slap a 200% tariff on foreign-made pharmaceuticals. That would roil the $200 billion-plus ...
1hon MSN
The hot flashes and night sweats that plague breast cancer survivors during years-long hormone-suppressing therapy are eased ...
The FDA will allow a new dosing schedule for Eli Lilly’s Alzheimer’s drug Kisunla that could lessen a known side effect of ...
The benefit-risk balance is tipping more in favor of Eli Lilly’s Kisunla in early Alzheimer’s disease as the FDA approves a ...
Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved a label ...
The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...
The U.S. Food and Drug Administration approved changing the prescribing information for Eli Lilly's Alzheimer's drug Kisunla to allow more gradual dosing to lower the risk of a potentially dangerous ...
David Ajayi, a Nigerian-born data science leader, is redefining clinical research infrastructure and digital health systems ...
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results